Form 6-K NOVO NORDISK A S For: Jun 20

June 21, 2022 6:05 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.



Washington, D.C. 20549









Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


June 20, 2022




 (Exact name of Registrant as specified in its charter)



Novo Allé 

DK- 2880, Bagsvaerd 


(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F


Form 20-F [X]           Form 40-F [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes [  ]            No [X]


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________







Novo Nordisk A/S – Share repurchase programme


Bagsværd, Denmark, 20 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.


Under the programme initiated 3 May 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.


Since the announcement 13 June 2022, the following transactions have been made:



Number of

B shares


purchase price


value, DKK

Accumulated, last announcement 2,219,689 1,700,443,214
13 June 2022 90,000 775.35 69,781,669
14 June 2022 90,000 764.05 68,764,348
15 June 2022 85,000 758.21 64,447,656
16 June 2022 95,000 748.00 71,060,125
17 June 2022 90,000 754.81 67,932,958
Accumulated under the programme 2,669,689 2,042,429,969


The details for each transaction made under the share repurchase programme are published on



Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 14,731,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.


Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12- month period beginning 2 February 2022. As of 17 June 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 12,991,818 B shares at an average share price of DKK 757.73 per B share equal to a transaction value of DKK 9,844,234,990


Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Twitter, LinkedIn, and YouTube.


Further information

Ambre Brown Morley +45 3079 9289 [email protected]
Natalia Salomao Abrahao (US) +1 848 304 1027 [email protected]
Daniel Muusmann Bohsen +45 3075 2175 [email protected]
Ann Søndermølle Rendbæk +45 3075 2253 [email protected]
David Heiberg Landsted +45 3077 6915 [email protected]
Jacob Martin Wiborg Rode +45 3075 5956 [email protected]
Mark Joseph Root (US) +1 848 213 3219 [email protected]


Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd



+45 4444 8888


CVR no:

24 25 67 90

    Company announcement No 53 / 2022





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.


Date: June 20, 2022




Lars Fruergaard Jørgensen

Chief Executive Officer











Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

SEC Filings